Development of a UPLC-MS/MS assay for the quantitative determination of capecitabine, 5′-deoxy-5-fluorocytidine (5′-dFCR), 5′-deoxy-5-fluorouridine (5′-dFUR), 5′-fluorouracil (5-FU), and α-fluoro-β-alanine (FBAL)-MedSci.cn

Development of a UPLC-MS/MS assay for the quantitative determination of capecitabine, 5′-deoxy-5-fluorocytidine (5′-dFCR), 5′-deoxy-5-fluorouridine (5′-dFUR), 5′-fluorouracil (5-FU), and α-fluoro-β-alanine (FBAL)

Knikman, JE; De Vries, N; Rosing, H; Cats, A; Guchelaar, HJ; Beijnen, JH

Knikman, JE (通讯作者)，Netherlands Canc Inst, Div Pharmacol, Div Med Oncol, Amsterdam, Netherlands.;Knikman, JE (通讯作者)，Netherlands Canc Inst, Div Pharmacol, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands.

PHARMAZIE, 2023; 78 (8): 107

Abstract

Capecitabine is an anticancer agent and is the oral prodrug of 5-fluorouracil (5-FU). In this study, an ultra-high performance liquid chromatography c......

Full Text Link

Links

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

Development of a UPLC-MS/MS assay for the quantitative determination of capecitabine, 5′-deoxy-5-fluorocytidine (5′-dFCR), 5′-deoxy-5-fluorouridine (5′-dFUR), 5′-fluorouracil (5-FU), and α-fluoro-β-alanine (FBAL)

科室

工具

服务